Dual-Use Labeling
When manufacturers market a substance as an active pharmaceutical ingredient (API), current good manufacturing practices (CGMPs) apply and the manufacturing location must be registered with the US Food and Drug Administration (FDA) as a drug-manufacturing establishment. Although the United States Ph...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical Technology 2008-07, Vol.32 (7), p.102 |
|---|---|
| 1. Verfasser: | |
| Format: | Magazinearticle |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 102 |
| container_title | Pharmaceutical Technology |
| container_volume | 32 |
| creator | Carter, William D |
| description | When manufacturers market a substance as an active pharmaceutical ingredient (API), current good manufacturing practices (CGMPs) apply and the manufacturing location must be registered with the US Food and Drug Administration (FDA) as a drug-manufacturing establishment. Although the United States Pharmacopeia (USP) designation normally is used for APIs and the National Formulary (NF) designation is generally used for excipients, there are exceptions. When a substance is labeled as USP or USP-NF without further clarification, one could assume that the substance may be used either as an API or an excipient, that the substance was manufactured according to CGMPs for APIs, and that the manufacturing facility is registered with FDA. If the product is presented for use as an excipient only, then registration is not required. By having clear documentation indicating intended use for their products, these companies avoided having to defend their decision not to register the plants. |
| format | Magazinearticle |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_198244043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1548066111</sourcerecordid><originalsourceid>FETCH-LOGICAL-p96t-f7509d22955b060f96a319ea9c0264c12df56c366d7b0b64276e0379b5fc33ed3</originalsourceid><addsrcrecordid>eNotzLFOwzAQAFCrohIh7cAf0A-wdL6zz_GIQoFKkVjCHNmJXYGiJsTp_3eg09veRhSoDEhLlh9EoYwmiQbVo3jK-RcAqVJYiOe3qx_ld44vjQ9x_Lmcd2Kb_Jjj_m4p2vdjW3_K5uvjVL82cna8ymQNuAHRGROAITn2pFz0rgdk3SsckuGemAcbILBGyxHIumBSTxQHKsXhv52X6e8a89otcZ6WNXfKVag1aKIb_B0ywQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>198244043</pqid></control><display><type>magazinearticle</type><title>Dual-Use Labeling</title><source>Business Source Complete</source><source>Alma/SFX Local Collection</source><creator>Carter, William D</creator><creatorcontrib>Carter, William D</creatorcontrib><description>When manufacturers market a substance as an active pharmaceutical ingredient (API), current good manufacturing practices (CGMPs) apply and the manufacturing location must be registered with the US Food and Drug Administration (FDA) as a drug-manufacturing establishment. Although the United States Pharmacopeia (USP) designation normally is used for APIs and the National Formulary (NF) designation is generally used for excipients, there are exceptions. When a substance is labeled as USP or USP-NF without further clarification, one could assume that the substance may be used either as an API or an excipient, that the substance was manufactured according to CGMPs for APIs, and that the manufacturing facility is registered with FDA. If the product is presented for use as an excipient only, then registration is not required. By having clear documentation indicating intended use for their products, these companies avoided having to defend their decision not to register the plants.</description><identifier>ISSN: 1543-2521</identifier><identifier>EISSN: 2150-7376</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Descriptive labeling ; Federal regulation ; Good Manufacturing Practice ; Ingredients ; Manufacturers ; Manufacturing ; Pharmaceutical industry ; Registration ; Supply chains</subject><ispartof>Pharmaceutical Technology, 2008-07, Vol.32 (7), p.102</ispartof><rights>Copyright Advanstar Communications, Inc. Jul 2008</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Carter, William D</creatorcontrib><title>Dual-Use Labeling</title><title>Pharmaceutical Technology</title><description>When manufacturers market a substance as an active pharmaceutical ingredient (API), current good manufacturing practices (CGMPs) apply and the manufacturing location must be registered with the US Food and Drug Administration (FDA) as a drug-manufacturing establishment. Although the United States Pharmacopeia (USP) designation normally is used for APIs and the National Formulary (NF) designation is generally used for excipients, there are exceptions. When a substance is labeled as USP or USP-NF without further clarification, one could assume that the substance may be used either as an API or an excipient, that the substance was manufactured according to CGMPs for APIs, and that the manufacturing facility is registered with FDA. If the product is presented for use as an excipient only, then registration is not required. By having clear documentation indicating intended use for their products, these companies avoided having to defend their decision not to register the plants.</description><subject>Descriptive labeling</subject><subject>Federal regulation</subject><subject>Good Manufacturing Practice</subject><subject>Ingredients</subject><subject>Manufacturers</subject><subject>Manufacturing</subject><subject>Pharmaceutical industry</subject><subject>Registration</subject><subject>Supply chains</subject><issn>1543-2521</issn><issn>2150-7376</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2008</creationdate><recordtype>magazinearticle</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNotzLFOwzAQAFCrohIh7cAf0A-wdL6zz_GIQoFKkVjCHNmJXYGiJsTp_3eg09veRhSoDEhLlh9EoYwmiQbVo3jK-RcAqVJYiOe3qx_ld44vjQ9x_Lmcd2Kb_Jjj_m4p2vdjW3_K5uvjVL82cna8ymQNuAHRGROAITn2pFz0rgdk3SsckuGemAcbILBGyxHIumBSTxQHKsXhv52X6e8a89otcZ6WNXfKVag1aKIb_B0ywQ</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Carter, William D</creator><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RN</scope><scope>7RQ</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>889</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>U9A</scope></search><sort><creationdate>20080701</creationdate><title>Dual-Use Labeling</title><author>Carter, William D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p96t-f7509d22955b060f96a319ea9c0264c12df56c366d7b0b64276e0379b5fc33ed3</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Descriptive labeling</topic><topic>Federal regulation</topic><topic>Good Manufacturing Practice</topic><topic>Ingredients</topic><topic>Manufacturers</topic><topic>Manufacturing</topic><topic>Pharmaceutical industry</topic><topic>Registration</topic><topic>Supply chains</topic><toplevel>online_resources</toplevel><creatorcontrib>Carter, William D</creatorcontrib><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Pharmaceutical News Index</collection><collection>Career & Technical Education Database</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Pharmaceutical News Index (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical Technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carter, William D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual-Use Labeling</atitle><jtitle>Pharmaceutical Technology</jtitle><date>2008-07-01</date><risdate>2008</risdate><volume>32</volume><issue>7</issue><spage>102</spage><pages>102-</pages><issn>1543-2521</issn><eissn>2150-7376</eissn><abstract>When manufacturers market a substance as an active pharmaceutical ingredient (API), current good manufacturing practices (CGMPs) apply and the manufacturing location must be registered with the US Food and Drug Administration (FDA) as a drug-manufacturing establishment. Although the United States Pharmacopeia (USP) designation normally is used for APIs and the National Formulary (NF) designation is generally used for excipients, there are exceptions. When a substance is labeled as USP or USP-NF without further clarification, one could assume that the substance may be used either as an API or an excipient, that the substance was manufactured according to CGMPs for APIs, and that the manufacturing facility is registered with FDA. If the product is presented for use as an excipient only, then registration is not required. By having clear documentation indicating intended use for their products, these companies avoided having to defend their decision not to register the plants.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1543-2521 |
| ispartof | Pharmaceutical Technology, 2008-07, Vol.32 (7), p.102 |
| issn | 1543-2521 2150-7376 |
| language | eng |
| recordid | cdi_proquest_reports_198244043 |
| source | Business Source Complete; Alma/SFX Local Collection |
| subjects | Descriptive labeling Federal regulation Good Manufacturing Practice Ingredients Manufacturers Manufacturing Pharmaceutical industry Registration Supply chains |
| title | Dual-Use Labeling |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual-Use%20Labeling&rft.jtitle=Pharmaceutical%20Technology&rft.au=Carter,%20William%20D&rft.date=2008-07-01&rft.volume=32&rft.issue=7&rft.spage=102&rft.pages=102-&rft.issn=1543-2521&rft.eissn=2150-7376&rft_id=info:doi/&rft_dat=%3Cproquest%3E1548066111%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198244043&rft_id=info:pmid/&rfr_iscdi=true |